Contraception today

Annals of the New York Academy of Sciences

Volumn 1092, Issue , 2006, Pages 1-32

  Benagiano, Giuseppe ^a,b   Bastianelli, Carlo ^a   Farris, Manuela ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Switzerland)

Author keywords

Contraception; Emergency contraceptives; Hormonal contraceptives; Intrauterine devices; Sexual behavior

Indexed keywords

ALGESTONE ACETOFENIDE PLUS ESTRADIOL ENANTHATE; ANTIGESTAGEN; CONTRACEPTIVE VACCINE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ELCOMETRINE; ESTRADIOL; ESTRADIOL CIPIONATE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETONOGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; LOW DOSE ORAL CONTRACEPTIVE; MEDROXYPROGESTERONE ACETATE; MESTRANOL; MIFEPRISTONE; MISOPROSTOL; NOMEGESTROL; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ENANTATE; NORETYNODREL; NOVAFEM; PATECTRO; PROGERING; PROGESTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CONTRACEPTIVE AGENT; POSTCOITUS CONTRACEPTIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMENORRHEA; BLEEDING; BLOATING; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; CONDOM; CONFERENCE PAPER; CONTRACEPTION; DEVELOPING COUNTRY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EMERGENCY CONTRACEPTION; FERTILITY; HEADACHE; HEALTH SURVEY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; MENORRHAGIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; ORAL CONTRACEPTION; OVULATION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SITE REACTION; SPOTTING; STEROID RELEASE; SUSTAINED RELEASE FORMULATION; SYNTHESIS; UNSPECIFIED SIDE EFFECT; UTERUS; VAGINA RING; FEMALE; HEALTH; MALE; REVIEW; UTILIZATION REVIEW;

CONDOMS; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVES, POSTCOITAL; FEMALE; HUMANS; MALE; SEXUALLY TRANSMITTED DISEASES; WORLD HEALTH;

EID: 34247208577     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1365.002     Document Type: Conference Paper

References (117)

1. BENAGIANO, G. 2002. Male and female reproductive strategies. Edwards symposium, Reprod. BioMed. Online, 4(Suppl. 1): 72-76.
2. WRANGHAM, R. & D. PETERSON. 1996. Demonic males: apes and the origin of human violence. Mariner Books. London.
3. NISHIDA, T. & M. HIRAIWA-HASEGAWA. 1987. Chimpanzees and bonobos; cooperative relationship among males. In Primate Societies. B.B. Smuts, D.L. Cheney, R.M. Seyfart, et al. Eds.: 165-177. Chicago University Press, Chicago.
4. DE WAAL, F.M.B. 1987. Tension regulation and non reproductive functions of sex in captive bonobos (Pan panicus). Nat. Geo. Res. 3: 318-335.
5. BAIRD, D. & A.F. GLASIER. Science, medicine and the future: contraception. Brit. Med. J. 319: 969-972.
6. UN POPULATION DIVISION. 2001. World Population Prospects: The 2000 Revision. United Nations, Department of Economic and Social Affairs (New York) ESA/P/WP.165.
7. UN POPULATION DIVISION. 2004. World Fertility Report 2003. United Nations, Department of Economic and Social Affairs. New York.
8. st century: a comprehensive study across five European countries. Eur. J. Contrac. Reprod. Health Care 9: 57-68.
9. ETHIOPIA DEMOGRAPHIC AND HEALTH SURVEY. 2005. Preliminary Report. Ethiopia Central Statistical Agency and ORC Macro. Calverton, UK.
10. BENAGIANO, G. & F.M. PRIMIERO. 1998. Safety of modern oral contraception: the options for women. Hum. Reprod. Update 5: 633-638.
11. SULLIVAN, H. et al. 1999. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil. Steril. 72: 115-120.
12. HAMPTON, R.M. et al. 2001. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Ciclen Lo) with the oral contraceptive Fe 1/20. Contraception 63: 289-295.
13. KAUNITZ, A.M. 2000. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and Ortho Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomised clinical trial. Contraception 61: 25-302.
14. HIRVONEN, E., M. MALKONEN & V. MANNINEN. 1981. Effects of different progestogens on lipoproteins during post-menopausal replacement therapy. N. Engl. J. Med. 304: 560-563.
15. JUNCHEN, M. et al. 1995. Dienogest: Bindungs-studien an veschienden Rezeptor-und Serumprotein. In Dienogest- Praklink und Klinik eines neuen Gestagenes. Walter de Gruyter Verlag. A.T. Teichman. Ed.: Berlin. 119-133.
16. HABENICHT, U.-F. 2005. Personal communication.
17. FOIDART, J.M. et al. 2000.Acomparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care 5: 124-134.
18. HUBER, H.J. et al. 2000. Efficacy tolerability of a monophasic oral contraceptive containing ethinil estradiol and drospirenone. Eur. J. Contracept. Reprod. Health Care 5: 25-35.
19. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. UNDP/UNFPA/WHO/WORLD BANK. 1999. Annual Technical Report 1998. WHO/RHR/00/9, World Health Organization, Geneva. 92.
20. FFPRHC, CLINICAL EFFECTIVENESS UNIT. 2003. FFPRHC guidance: first prescription of combined oral contraception. J. Fam. Plann. Reprod. Health Care 29: 209-223.
21. WORLD HEALTH ORGANIZATION. 2005. Selected Practice Recommendations for Contraceptive Use. Second edition. World Health Organisation. Geneva.
22. KAUNITZ, A.M. 2005. Beyond the pill: new data and options in hormonal and intrauterine contraception. Am. J. Obstet. Gynecol. 192: 998-1004.
23. TRUSSELL, J. 2004. Contraceptive efficacy. In Contraceptive technology. R.A. Hatcher, J. Trussell, F. Stewart et al., Eds.: 18th edition. New York, Ardent Media.
24. RICE, C. et al. 1996. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum. Reprod. 11: 737-740.
25. SKOUBY, S.O. 1982. Laboratory and clinical assessment of a new progestational compound desogestrel. Acta Obstet. Gynaecol. Scand. Suppl. 111: 7-11.
26. VIINIKKA, L. et al. 1979. Metabolism of a new synthetic progestogen, Org 2969, in female volunteers. Investigations into the pharmacokinetics after a single dose. Eur. J. Clin. Pharmacol. 15: 349-355.
27. RICE, C.F. et al. 1999. A comparison of the inhibition of ovulation, achieved by desogestrel 75μg and levonorgestrel 30μg daily. Hum. Reprod. 14: 982-985.
28. RICE, C.F. et al. 1998. The effect of desogestrel 75μg and levonorgestrel 30μg on the endometrium and bleeding patterns over one year. Br. J. Obstet. Gynaecol. 105 (Suppl. 17): 114.
29. BENAGIANO, G. & F.M. PRIMIERO. 2003. The newminipill with 75 g of desogestrel. In Challenges on Women's Health and Diseases: Gynecologic and Reproductive Issues. Ann. N. Y. Acad. Sci. 997: 163-173.
30. HUSSAIN, A. & F. AHSAN. 2005. The vagina as a route for systemic drug delivery. J. Control Release 103: 301-313.
31. UPADHYAY, U.D. 2005. New contraceptive choices. Population Reports. Series M, No.19. Johns Hopkins Bloomberg School of Public Health. Baltimore, MD.
32. DIAZ, S. 1999. Contraceptive vaginal rings. International Planned Parenthood Federation Medical Bulletin. 33: 3-4.
33. BJARNADOTTIR, R.I., M. TUPPURAINEN & S.R. KILLICK. 2002. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am. J. Obstet. Gynecol. 186: 389-395.
34. JOHANSSON, E.D. & R. SITRUK-WARE. 2004. New delivery systems in contraception: vaginal rings. Am. J. Obstet. Gynecol. 190 (Suppl 4): S54-S59.
35. MASSAI, R. et al. 2000. Vaginal rings for contraception in lactating women. Steroids 65: 703-707.
36. SITRUK-WARE, R. 2004. Contraceptive development at the Population Council. Quoted by: Population Reports (31).
37. SMALLWOOD, G.H. et al. 2001. Efficacy and safety of a transdermal contraceptive system. Obstet. Gynecol. 98: 799-805.
38. STEWART, F.H. et al. 2005. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet. Gynecol. 105: 1389-1396.
39. AUDET, M.C. et al. 2001. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. J. Am. Med. Assn. 285: 2347-2354.
40. ZIEMAN, M. et al. 2002. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil. Steril. 77(Suppl 2): S13-S18.
41. HEGER-MAHN, D. et al. 2004. Combined ethinyl estradiol/ gestodene contraceptive patch: two-center, open label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. Eur. J. Contracept. Reprod. Health Care 9: 173-181.
42. YOUNG, E. 2003. Spray-on female contraceptive to start trial. New Scientist. Nov. 27, 2003.
43. SITRUK-WARE, R. et al. 2003. Nestorone: clinical applications for contraception and HRT. Steroids 68: 907-913.
44. ERMINI, M. et al. 1976. Effetto dei dispositivi intrauterine liberanti progesterone sull'asse ipotalamo-ipofiso-ovarico nella donna. Patol. Clin. Ostet. Ginec. 4: 109-115.
45. WAN, L.S. et al. 1977. Effects of the progestasert on the menstrual pattern, ovarian steroid and endometrium. Contraception 16: 417-434.
46. HAGENFELDT, K. & B.M. LANDGREN. 1975. Contraception by intrauterine release of progesterone-effects on endometrial trace elements enzymes and steroids. J. Steroid Biochem. 6: 895-898.
47. HAGENFELDT, K. et al. 1977. Biochemical and morphological changes in the human endometrium induced by the progestasert device. Contraception 16: 183-197.
48. ERMINI, M., F. CARPINO, V. PETROZZA & G. BENAGIANO. 1989. Distribution and effect on the endometrium of progesterone release from a progestasert device. Hum. Reprod. 4: 221-228.
49. SHAW, S.T. et al. 1981. Effect of progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study. Am. J. Obstet. Gynecol. 141: 829-839.
50. SNOWDEN, R. 1977. The progestasert and ectopic pregnancy. Br. Med. J. 2: 1600-1601.
51. NILSSON, C.-G., E.D.B. JOHANSSON & T. A. LUUKKAINEN. 1976. d-norgestrel-releasing IUD. Contraception 13: 503-514.
52. FACULTY OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE. FFPRHC GUIDANCE. 2004. The levonorgestel releasing system (LNG-IUS) in contraception and reproductive health. J. Fam. Plann. Reprod. Health Care 30: 99-109.
53. BARBOSA, I. et al. 1990. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 42: 51-66.
54. NILSSON, C.G., P.L.A. LAHTEEMAKI & T. LUUKKAINEN. 1984. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil. Steril. 41: 52-55.
55. FRENCH, R.S. et al. 2000. Levonorgestrel-releasing (20 g/day) intrauterine system (Mirena) compared with other method of reversible contraception. Br. J. Obstet. Gynecol. 107: 1218-1225.
56. LUKKAINEN, T. 2000. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 65: 699-702.
57. IRVINE, G.A. et al. 1998. Randomised comparative trial of levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br. J. Obstet. Gynecol. 105: 592-598.
58. LUUKKAINEN, T., P.L.A. LAHTEENMAKI & J. TOIVONEN. 1990. Levonorgestrel-releasing intrauterine device. Ann. Med. 22: 85-90.
59. ANDERSSON, K.,V. ODLIND & G. RYBO. 1994. Levonorgestrel releasing and copper releasing (Nova T) IUDs during five years of use: a randomised trial. Contraception 49: 56-72.
60. RIVERA, R., I. YACOBSON & D. GRIMES. 1999. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am. J. Obstet. Gynecol. 1999 181: 1263-1269.
61. JONSSON, B., B.-M. LANDGREN & P. ENEROTH. 1991. Effects of various IUDs on the composition of cervical mucus. Contraception 43: 447-458.
62. ANDERSSON, K., I. BATAR & G. RYBO. 1992. Return to fertility after removal of a levonorgestrel releasing intrauterine device and Nova T. Contraception 46: 575-584.
63. FRENCH, R.S. et al. 2000. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraception: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol. Assess. 4: 1-107.
64. STEWART, A. et al. 2001. Effectiveness of the levonorgestrel releasing intrauterine system in menorrhagia: a systematic review. Br. J. Obstet. Gynecol. 108: 74-86.
65. NEWTON, J.R., C. D'ARCANGUES & P.E. HALL. 1994. A review of "once-amonth" combined injectable contraceptives. J. Obstet. Gynecol. 4 (Suppl 1): S1-S34.
66. RAHIMY, M.H. & K.K. RYAN. 1999. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 60: 189-200.
67. INTERNATIONAL PLANNED PARENTHOOD FEDERATION. 2003. Directory of hormonal contraceptives.http:// contraceptive.ippf.org/(rlyna245m2vhrjfqdj304v45)/Default.aspx International Planned Parenthood Federation, London.
68. BAHAMONDES, L. et al. 1997. Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem. Contraception 56: 301-304.
69. SIVIN, I. et al. 1998. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Hum. Reprod. 13: 3371-3378.
70. CROXATTO, H.B. & N. MAKARAINEN. 1998. Pharmacodinamics and efficacy of Implanon. Contraception 58: 91S-97S.
71. DEVOTO, L. et al. 1997. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum. Reprod. 12: 708-713.
72. SIVIN, I. et al. 2004. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception 69: 137-144.
73. MASSAI, M.R. et al. 2001. Contraceptive efficacy and clinical performance of nestorone implants in postpartum women. Contraception 64: 369-376.
74. WILDEMEERSCH, D. 2001. Further information and recommendations to prevent perforation with the frameless GyneFix IUD. J. Fam. Plann. Reprod. Health Care 27: 241.
75. BROCKMEYER, A., M. KISHEN & A. WEBB. 2004. New GyneFix introducer. J. Fam. Plann. Reprod. Health Care 30: 65.
76. O'BRIEN, P.A. & C. MARFLEET. 2005. Frameless versus classical intrauterine device for contraception. Cochrane Database Syst. Rev. 25: CD 003282.
77. DELBARGE, W. et al. 2002. Return to fertility in nulliparous and parous women after removal of the GyneFix intrauterine contraceptive system. Eur. J. Contracept. Reprod. Health Care 7: 24-30.
78. CAO, X et al. 2004. Three-year efficacy and acceptability of the GyneFix 200 intrauterine system. Contraception 69: 207-211.
79. WU, S., J. HU & D. WILDEMEERSCH. 2000. Performance of the frameless GyneFix and the TCu380A IUDs in a 3-year multicenter, randomized, comparative trial in parous women. Contraception 61: 91-98.
80. WILDEMEERSCH, D. et al. 2002. Development of a miniature, low-dose, frameless intrauterine levonorgestrel-releasing system for contraception and treatment: a review of initial clinical experience. Reprod. Biomed. Online 4: 71-82.
81. WILDEMEERSCH, D., E. SCHACHT & P. WILDEMEERSCH. 2002. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study. Contraception 66: 93-99.
82. WILDEMEERSCH, D. et al. 2004. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Proceedings 8th Congress of the European Society of Contraception, Edinburgh, Scotland. June 23-36.
83. NAZ, K.R. et al. 2005. Recent advances in contraceptive vaccine development: a mini-review. Hum. Reprod. 20: 3271-3283.
84. MILLER, L.A., B.E. JOHNSON & G.J. KILLIAN. 2000. Immunocontraception of white tailed deer with nRH vaccine. Am. J. Reprod. Immunol. 44: 266-274.
85. HSU, C.T. et al. 2000. Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor binding domain-conjugated GnRH repeats. Cancer Res. 60: 3701-3705.
86. SURI, A. 2005. Sperm-based contraceptive vaccines: current status, merits and development. Expert Rev. Mol. Med. 7: 1-16.
87. NAZ, R.K. 2005. Contraceptive vaccines. Drugs 65: 593-603.
88. GUPTA, S.K. et al. 2004. Update on zona pellucida glycoproteins based contraceptive vaccines. J. Reprod. Immunol. 62: 79-89.
89. STEVENS, V.G. 1973. Immunization of female baboons with hapten-coupled gonadotropins. Obstet. Gynecol. 42: 496-504.
90. PALA, A., M. ERMINI, L. CARENZA & G. BENAGIANO. 1976. Immunization with hapten-coupled HCG-beta subunit and its effect on the menstrual cycle. Contraception 14: 579-593.
91. STEVENS, V.C. 1974. Fertility control through active immunization using placenta proteins: Karolinska Symposia on Research Methods in Reproductive Biology. 7th Symposium: In Immunological Approaches to Fertility Control. E. Diczfalusy, Ed.: 357-369. Bogtrykkeriet Forum. Copenhagen.
92. TALWAR, G.P. 1974. Fertility control through active immunization using placenta proteins: Karolinska Symposia on Research Methods in Reproductive Biology. 7th Symposium: In Immunological Approaches to Fertility Control. E. Diczfalusy Ed.: 370-386. Bogtrykkeriet Forum. Copenhagen.
93. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. WORLD HEALTH ORGANIZATION. 1991. Annual Technical Report 1990. WHO/HRP/90/91, World Health Organization. Geneva. 99.
94. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. UNDP/UNFPA/WHO/World Bank. 2000. Annual Technical Report 1999. WHO/RHR/00/9,World Health Organization, Geneva. 127.
95. TALWAR, G.P. et al. 1994. A vaccine that prevents pregnancy in women. Proc. Natl. Acad. Sci. USA 91: 8532-8536.
96. HARVEY, S.M. et al. 2004. Protecting against both pregnancy and disease: predictors of dual method use among a sample of women. Women Health 39: 25-43.
97. BRADY, M. 2003. Preventing sexually transmitted infections and unintended pregnancy, and safeguarding fertility: triple protection needs of young women. Reprod. Health Matters 11: 134-141.
98. YUZPE, A.A. 1974. Post-coital contraception - A pilot study. J. Reprod. Med. 30: 12-18.
99. HOFFMAN, K.O. 1984. Postcoital contraception: experiences with ethynil estradiol/norgestrel and levonorgestrel only. In Proceedings of the XIth Congress on Fertility and Sterility. R.F. Harrison, J. Bonnar & W. Thompson. Eds.: 311-316. MTP Press. Lancaster.
100. WORLD HEALTH ORGANIZATION. TASK FORCE ON POST-OVULATORY METHODS FOR FERTILITY REGULATION. (SPECIAL PROGRAMME FOR RESEARCH TRAINING IN HUMAN REPRODUCTION.) TASK FORCE ON POSTOVULATORY METHODS OF FERTILITY REGULATION. 1998. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 352: 428-433.
101. TASK FORCE ON POST-OVULATORY METHODS FOR FERTILITY REGULATION. 1987. Post coital contraception with levonorgestrel during the peri-ovulatory phase of the menstrual cycle. Contraception 36: 257-286.
102. BENAGIANO, G., M. FARRIS & C. BASTIANELLI. 2005. Emergency contraception. In Human Reproduction. A.R. Genazzani, J. Schenker, P.G. Artini, T. Simoncini, Eds.: 40-47. CIC Edizioni Internazionali. Roma. 2005.
103. LAHTEEMAKI, P. et al. 1987. Pharmacokinetics and metabolism of RU-486. J. Steroid. Biochem. 27: 859-865.
104. VON HERTZEN, H. et al. 2000. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet 360: 1803-1810.
105. WORLD HEALTH ORGANIZATION. TASK FORCE ON POST-OVULATORY METHODS FOR FERTILITY REGULATION. 1999. Comparison of three single doses of mifepristone as emergency contraception: a randomized trial. Lancet 353: 697-702.
106. VON HERTZEN, H. & P.F.A. VAN LOOK. 1996. Research on new methods of emergency contraception. Int. Fam. Plann. Perspect. 22: 62-68.
107. VON HERTZEN, H. & G. PIAGGIO. 2003. Levonorgestrel and mifepristone in emergency contraception. Steroids 68: 1107-1113.
108. CROXATTO, H.B. et al. 2002. Effects of the Yuzpe regimen, given during the follicular phase on ovarian function. Contraception 65: 121-128.
109. HAPANGAMA, D., A.F. GLASIER & D.T. BAIRD. 2001. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. Contraception 63: 123-129.
110. LANDGREN, B.M. et al. 1989 The effect of levonorgestrel administered in large doses at different stages of the cycles on ovarian function and endometrial morphology. Contraception 39: 275-289.
111. DURAND, M. et al. 2001. On the mechanism of action of short-term levonorgestrel administration in emergency contraception. Contraception 64: 227-234.
112. KESSERU, E. et al. 1974. The hormonal peripheral effects of dl-norgestrel in post-coital contraception. Contraception 10: 411-424.
113. CROXATTO, H.B. et al. 2001. Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. Contraception 63: 111-121.
114. SWAHN, M.L. et al. 1996. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle. Acta Obstet. Gynecol. Scand. 75: 738-744.
115. MARIONS, L. et al. 2002. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet. Gynecol. 100: 65-71.
116. CROXATTO, H.B. 2002. Pillules contraceptives d'urgence: comment fonctionnentelles? IPPF Med. Bull. 36: 1-2.
117. ASHOK, P.W. et al. 2002. A randomized study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. Br. J. Obstet. Ginec. 109: 553-560.